Triapine
Astrocytoma, IDH-Mutant, Grade 2
National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Astrocytoma, IDH-Mutant, Grade 2 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
Ipilimumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Pembrolizumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Nivolumab Neonc Technologies, Inc. | Phase 1/2 | CC |
Carboplatin Neonc Technologies, Inc. | Phase 1/2 | CC |
Regorafenib Neonc Technologies, Inc. | Phase 1/2 | CC |
neo212 Neonc Technologies, Inc. | Phase 1/2 | CC |
Telaglenastat National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Triapine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →